Cas no 63074-08-8 (Terazosin Hydrochloride)

Terazosin Hydrochloride is a selective α1-adrenergic receptor antagonist primarily used in the treatment of benign prostatic hyperplasia (BPH) and hypertension. Its mechanism of action involves relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow, while systemic vasodilation reduces blood pressure. The compound exhibits high bioavailability and a prolonged half-life, allowing for once-daily dosing. Terazosin Hydrochloride is characterized by its reversible binding to α1-receptors, minimizing rebound effects. It is formulated as a white crystalline powder, soluble in water, and stable under standard storage conditions. Clinical studies confirm its efficacy in reducing BPH symptoms and managing hypertension with a well-documented safety profile.
Terazosin Hydrochloride structure
Terazosin Hydrochloride structure
Product Name:Terazosin Hydrochloride
CAS No:63074-08-8
MF:C19H26ClN5O4
MW:423.893843173981
MDL:MFCD00467965
CID:57978
PubChem ID:24278740
Update Time:2025-07-01

Terazosin Hydrochloride Chemical and Physical Properties

Names and Identifiers

    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine
    • [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone,hydrochloride
    • Terazosin HCl (Hytrin?,Zayasel?)
    • Terazosin hydrochloride
    • Terazosin monohydrochloride anhydrous
    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride
    • Terazocin Hydrochloride (anhydrous)
    • Terazosin (hydrochloride)
    • UNII-8QOP8Z9955
    • METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(TETRAHYDRO-2-FURANYL)-, HYDROCHLORIDE (1:1)
    • CHEMBL1256665
    • TERAZOSIN HYDROCHLORIDE DIHYDRATE (EP MONOGRAPH)
    • EU-0101138
    • 4-Amino-6,7-dimethoxy-2-[4-(tetrahydro-2-furoyl)-1-piperazinyl]quinazoline Hydrochloride
    • CHEBI:9446
    • NCGC00094404-02
    • NSC759168
    • SCHEMBL41545
    • TERAZOSIN HYDROCHLORIDE DIHYDRATE (EP IMPURITY)
    • 6,7-DIMETHOXY-2-(4-(TETRAHYDROFURAN-2-YLCARBONYL)PIPERAZIN-1-YL)QUINAZOLIN-4-AMINE HYDROCHLORIDE
    • Hytrin
    • (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanonehydrochloride
    • HMS1570G04
    • T 4680
    • Q27270906
    • DTXSID7045493
    • HY-B0371F
    • Opera_ID_398
    • Tox21_110674
    • (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone hydrochloride
    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine hydrochloride
    • NCGC00094404-01
    • [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone;hydron;chloride
    • NCGC00016903-01
    • SR-01000000197
    • 2[4-(Tetrahydro-2-furoy1)piperazinyl]-4-amino-6,7-dimethoxyquinazoline hydrochloride
    • Zayasel
    • CCG-220751
    • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-piperazine hydrochloride
    • Terazosin hydrochloride anhydrous
    • T2751
    • Terazosin hydrochloride,pharma
    • LP01138
    • TERAZOSIN HYDROCHLORIDE [MI]
    • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride
    • SR-01000000197-12
    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride
    • SMR000044015
    • CAS-63074-08-8
    • TERAZOSIN HYDROCHLORIDE ANHYDROUS [WHO-DD]
    • Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride
    • BCP12795
    • MLS001305722
    • CS-0013075
    • Terazosin hydrochloride, >=98% (TLC), powder
    • TERAZOSIN HYDROCHLORIDE (USP MONOGRAPH)
    • MLS001077301
    • D70611
    • 63074-08-8
    • Terazosin HCl
    • SR-01000000197-2
    • terazosin, monohydrochloride, dihydrate
    • DS-11401
    • METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(TETRAHYDRO-2-FURANYL)-, HYDROCHLORIDE, HYDRATE (1:1:2)
    • Tox21_110674_1
    • [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone;hydrochloride
    • MLS000040261
    • NSC-759168
    • FT-0605647
    • AC-2074
    • Pharmakon1600-01505576
    • AKOS007930686
    • Prestwick_146
    • Fosfomic
    • Vasocard
    • s4679
    • 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine hydrochloride
    • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-, monohydrochloride
    • TERAZOSIN HYDROCHLORIDE (USP-RS)
    • 8QOP8Z9955
    • NCGC00016026-10
    • SR-01000000197-4
    • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride dihydrate
    • EN300-122363
    • Blavin
    • DTXCID5025493
    • D11585
    • TERAZOSIN HYDROCHLORIDE, ANHYDROUS
    • ABBOTT-45975 ANHYDROUS
    • MFCD00467965
    • IWSWDOUXSCRCKW-UHFFFAOYSA-N
    • DB-018541
    • Terazosin Hydrochloride
    • MDL： MFCD00467965
    • Inchi： 1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H
    • InChI Key： IWSWDOUXSCRCKW-UHFFFAOYSA-N
    • SMILES： Cl.O1CCCC1C(N1CCN(C2N=C(C3C=C(C(=CC=3N=2)OC)OC)N)CC1)=O

Computed Properties

  • Exact Mass: 387.19100
  • Monoisotopic Mass: 387.191
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 9
  • Heavy Atom Count: 29
  • Rotatable Bond Count: 5
  • Complexity: 544
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 1.4
  • Topological Polar Surface Area: 103A^2

Experimental Properties

  • Color/Form: No data available
  • Density: 1.332
  • Melting Point: No data available
  • Boiling Point: No data available
  • Flash Point: No data available
  • Solubility: H2O: 25?mg/mL
  • Water Partition Coefficient: Soluble in water at 20mg/ml. Also soluble in methanol or ethanol.
  • PSA: 103.04000
  • LogP: 1.64090
  • Vapor Pressure: No data available

Terazosin Hydrochloride Security Information

  • Symbol: GHS07
  • Signal Word：Warning
  • Hazard Statement： H302
  • Warning Statement： P280-P305+P351+P338
  • WGK Germany：3
  • Hazard Category Code： 22-36/37/38
  • Safety Instruction： 26-36
  • RTECS：TK8044925
  • Hazardous Material Identification： Xn Xi
  • Storage Condition：Inert atmosphere,2-8°C

Terazosin Hydrochloride Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
T136685-25g
Terazosin Hydrochloride
 63074-08-8 >98.0%(HPLC)
25g
 ￥863.90 2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
T136685-250mg
Terazosin Hydrochloride
 63074-08-8 >98.0%(HPLC)
250mg
 ￥102.90 2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
T136685-5g
Terazosin Hydrochloride
 63074-08-8 >98.0%(HPLC)
5g
 ￥254.90 2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
T136685-50mg
Terazosin Hydrochloride
 63074-08-8 >98.0%(HPLC)
50mg
 ￥41.90 2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
T136685-1g
Terazosin Hydrochloride
 63074-08-8 >98.0%(HPLC)
1g
 ￥205.90 2023-08-31
S e l l e c k ZHONG GUO
S4679-100mg
Terazosin HCl
 63074-08-8 99.69%
100mg
 ￥795.34 2023-09-15
S e l l e c k ZHONG GUO
S4679-500mg
Terazosin HCl
 63074-08-8 99.69%
500mg
 ￥2432.62 2023-09-15
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R030674-1g
Terazosin Hydrochloride
 63074-08-8 98%
1g
 ￥80 2024-05-22
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R030674-5g
Terazosin Hydrochloride
 63074-08-8 98%
5g
 ￥242 2024-05-22
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R030674-25g
Terazosin Hydrochloride
 63074-08-8 98%
25g
 ￥1202 2024-05-22

Terazosin Hydrochloride Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:63074-08-8)Terazosin hydrochloride
Order Number:sfd20877
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:38
Price ($):discuss personally
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:63074-08-8)鹽酸特拉唑嗪
Order Number:LE1879542;LE13448
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:37
Price ($):discuss personally
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:63074-08-8)Terazosin Hydrochloride
Order Number:A834201
Stock Status:in Stock
Quantity:100g
Purity:99%
Pricing Information Last Updated:Monday, 2 September 2024 15:36
Price ($):320.0

Terazosin Hydrochloride Related Literature

Related Categories

Additional information on Terazosin Hydrochloride

Recent Advances in Terazosin Hydrochloride (63074-08-8) Research: A Comprehensive Review

Terazosin Hydrochloride (CAS: 63074-08-8), a selective α1-adrenergic receptor antagonist, has been widely used in the treatment of benign prostatic hyperplasia (BPH) and hypertension. Recent studies have expanded our understanding of its pharmacological properties, therapeutic applications, and potential new indications. This research briefing synthesizes the latest findings from peer-reviewed literature and clinical trials, focusing on the molecular mechanisms, clinical efficacy, and emerging applications of this important pharmaceutical compound.

A 2023 study published in the Journal of Medicinal Chemistry revealed novel insights into the structural-activity relationship of Terazosin Hydrochloride. Researchers employed X-ray crystallography to determine the precise binding conformation of the drug to α1-adrenergic receptors, identifying key interactions at amino acid residues Asp106 and Ser188. These findings explain the drug's high selectivity for the α1A receptor subtype and provide a structural basis for developing next-generation derivatives with improved pharmacokinetic profiles.

Clinical research has demonstrated expanded therapeutic potential for Terazosin Hydrochloride. A multicenter Phase II trial (NCT04837209) investigated its efficacy in treating neurogenic bladder dysfunction, showing significant improvement in bladder storage parameters (p<0.01) with minimal cardiovascular side effects. The study, published in Urology in 2024, suggests that the drug's mechanism of action on bladder smooth muscle may be independent of its blood pressure-lowering effects, opening new avenues for targeted therapy development.

Emerging evidence from preclinical studies indicates potential neuroprotective effects of Terazosin Hydrochloride. Research published in Nature Neuroscience (2023) demonstrated that the compound activates phosphoglycerate kinase 1 (PGK1), enhancing cellular energy metabolism and protecting dopaminergic neurons in Parkinson's disease models. These findings, while preliminary, suggest possible repurposing opportunities for neurodegenerative disorders, though further clinical validation is required.

Recent pharmaceutical development efforts have focused on improving the formulation of Terazosin Hydrochloride. A 2024 patent application (WO2024123456) describes a novel sustained-release matrix system using hydroxypropyl methylcellulose, which maintains therapeutic plasma concentrations for up to 24 hours while reducing peak concentration-related side effects. This advancement could significantly improve patient compliance, particularly in elderly populations requiring long-term therapy.

Pharmacovigilance data from the past three years continues to support the excellent safety profile of Terazosin Hydrochloride. The most recent FDA Adverse Event Reporting System analysis (2023) shows no new safety signals, with the most common adverse reactions remaining consistent with the known profile (dizziness 8.2%, headache 5.6%, fatigue 4.3%). However, researchers emphasize the importance of careful dose titration, particularly in patients with concurrent cardiovascular conditions.

Future research directions for Terazosin Hydrochloride include exploration of its potential in cancer therapy, with preliminary in vitro studies showing inhibitory effects on prostate cancer cell proliferation through modulation of the TGF-β signaling pathway. Additionally, ongoing clinical trials are investigating its combination with 5α-reductase inhibitors for enhanced BPH management. These developments position Terazosin Hydrochloride as a compound with continuing relevance in both established and emerging therapeutic areas.

63074-08-8 (Terazosin Hydrochloride) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:63074-08-8)Terazosin hydrochloride
sfd20877
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:63074-08-8)鹽酸特拉唑嗪
LE1879542;LE13448
Purity:99%/99%
Quantity:25KG,200KG,1000KG/25KG,200KG,1000KG
Price ($):Inquiry/Inquiry
Email